NYSE:GSK - GlaxoSmithKline Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$39.85 -0.18 (-0.45 %)
(As of 05/28/2018 01:23 AM ET)
Previous Close$39.85
Today's Range$39.77 - $39.98
52-Week Range$34.52 - $44.53
Volume1.88 million shs
Average Volume2.39 million shs
Market Capitalization$98.81 billion
P/E Ratio13.84
Dividend Yield5.27%
Beta0.82

About GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline logoGlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GSK
CUSIPN/A
Phone44-20-8047-5000

Debt

Debt-to-Equity Ratio3.90
Current Ratio0.61
Quick Ratio0.40

Price-To-Earnings

Trailing P/E Ratio13.84
Forward P/E Ratio13.79
P/E Growth2.09

Sales & Book Value

Annual Sales$38.89 billion
Price / Sales2.54
Cash Flow$3.8391 per share
Price / Cash10.38
Book Value$2.01 per share
Price / Book19.83

Profitability

EPS (Most Recent Fiscal Year)$2.88
Net Income$1.97 billion
Net Margins3.50%
Return on Equity144.84%
Return on Assets10.29%

Miscellaneous

Employees99,827
Outstanding Shares2,479,430,000

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline declared a quarterly dividend on Thursday, April 26th. Investors of record on Friday, May 11th will be paid a dividend of $0.5298 per share on Thursday, July 12th. This represents a $2.12 annualized dividend and a yield of 5.32%. The ex-dividend date of this dividend is Thursday, May 10th. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) issued its quarterly earnings results on Wednesday, April, 25th. The pharmaceutical company reported $0.68 earnings per share for the quarter, missing analysts' consensus estimates of $0.70 by $0.02. The pharmaceutical company earned $10.04 billion during the quarter, compared to analyst estimates of $10.26 billion. GlaxoSmithKline had a return on equity of 144.84% and a net margin of 3.50%. View GlaxoSmithKline's Earnings History.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for GlaxoSmithKline.

What price target have analysts set for GSK?

12 brokerages have issued twelve-month target prices for GlaxoSmithKline's stock. Their forecasts range from $35.85 to $40.00. On average, they expect GlaxoSmithKline's share price to reach $38.6167 in the next twelve months. View Analyst Ratings for GlaxoSmithKline.

Who are some of GlaxoSmithKline's key competitors?

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:
  • Ms. Emma Walmsley, Chief Exec. Officer & Director (Age 48)
  • Mr. Simon P. Dingemans, Chief Financial Officer & Exec. Director (Age 54)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 55)
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 56)
  • Mr. Daniel E. Troy, Sr. VP and Gen. Counsel

Has GlaxoSmithKline been receiving favorable news coverage?

Headlines about GSK stock have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GlaxoSmithKline earned a news sentiment score of 0.10 on Accern's scale. They also gave news headlines about the pharmaceutical company an impact score of 46.63 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by many different of institutional and retail investors. Top institutional investors include Royal Bank of Canada (0.86%), Fisher Asset Management LLC (0.54%), Federated Investors Inc. PA (0.17%), Northern Trust Corp (0.13%), Equity Investment Corp (0.13%) and Schafer Cullen Capital Management Inc. (0.08%). View Institutional Ownership Trends for GlaxoSmithKline.

Which major investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Millennium Management LLC, Federated Investors Inc. PA, SeaTown Holdings Pte. Ltd., PVG Asset Management Corp, Envestnet Asset Management Inc., SG Americas Securities LLC and Thrivent Financial for Lutherans. View Insider Buying and Selling for GlaxoSmithKline.

Which major investors are buying GlaxoSmithKline stock?

GSK stock was acquired by a variety of institutional investors in the last quarter, including Equity Investment Corp, Schafer Cullen Capital Management Inc., Fisher Asset Management LLC, BlackRock Inc., LPL Financial LLC, CIBC World Markets Inc., Northern Trust Corp and Summit Trail Advisors LLC. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $39.85.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $98.81 billion and generates $38.89 billion in revenue each year. The pharmaceutical company earns $1.97 billion in net income (profit) each year or $2.88 on an earnings per share basis. GlaxoSmithKline employs 99,827 workers across the globe.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]


MarketBeat Community Rating for GlaxoSmithKline (GSK)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  386 (Vote Outperform)
Underperform Votes:  720 (Vote Underperform)
Total Votes:  1,106
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GlaxoSmithKline (NYSE:GSK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for GlaxoSmithKline in the last 12 months. Their average twelve-month price target is $38.6167, suggesting that the stock has a possible downside of 3.09%. The high price target for GSK is $40.00 and the low price target for GSK is $35.85. There are currently 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.382.292.25
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.6167$38.6167$38.2125$40.95
Price Target Upside: 3.09% downside3.29% downside2.53% upside16.87% upside

GlaxoSmithKline (NYSE:GSK) Consensus Price Target History

Price Target History for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2018Deutsche BankReiterated RatingNeutralLowView Rating Details
4/4/2018BNP ParibasUpgradeNeutral ➝ OutperformMediumView Rating Details
3/22/2018Morgan StanleyUpgradeUnderweight ➝ Equal WeightMediumView Rating Details
2/15/2018CowenReiterated RatingHold$40.00LowView Rating Details
2/9/2018Kepler Capital MarketsUpgradeReduce ➝ HoldLowView Rating Details
2/5/2018JPMorgan Chase & Co.Reiterated RatingNeutralHighView Rating Details
1/16/2018BarclaysUpgradeEqual Weight ➝ OverweightLowView Rating Details
1/15/2018UBSReiterated RatingBuyMediumView Rating Details
11/30/2017ArgusLower Price TargetBuy$40.00LowView Rating Details
11/6/2017InvestecDowngradeBuy ➝ HoldN/AView Rating Details
10/26/2017Bank of AmericaDowngradeBuy ➝ NeutralN/AView Rating Details
7/27/2017CitigroupReiterated RatingNeutralLowView Rating Details
5/26/2017Berenberg BankUpgradeHold ➝ BuyLowView Rating Details
4/5/2017Exane BNP ParibasUpgradeUnderperform ➝ NeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy ➝ BuyLowView Rating Details
2/19/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
12/27/2016Goldman Sachs GroupReiterated RatingBuyN/AView Rating Details
10/26/2016Beaufort SecuritiesReiterated RatingBuyN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/AView Rating Details
8/17/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
(Data available from 5/28/2016 forward)

Earnings

GlaxoSmithKline (NYSE:GSK) Earnings History and Estimates Chart

Earnings by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Earnings Estimates

2018 EPS Consensus Estimate: $3.06
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.69$0.70$0.70
Q2 20181$0.82$0.82$0.82
Q3 20181$0.86$0.86$0.86
Q4 20181$0.68$0.68$0.68

GlaxoSmithKline (NYSE GSK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018        
4/25/20183/31/2018$0.70$0.68$10.2638 billion$10.0443 billionViewN/AView Earnings Details
2/7/2018n/a$0.69$0.72$9.8910 billion$10.1409 billionViewN/AView Earnings Details
10/25/2017Q3 2017$0.84$0.85$10.2189 billion$10.2634 billionViewN/AView Earnings Details
7/26/20176/30/2017$0.68$0.70$9.5216 billion$9.3597 billionViewN/AView Earnings Details
4/26/20173/31/2017$0.62$0.62$9.0867 billion$9.23 billionViewN/AView Earnings Details
2/8/201712/31/2016$0.57$0.65$9.2133 billion$9.4307 billionViewListenView Earnings Details
10/26/2016Q316$0.7730$0.83$8.9199 billion$9.9027 billionViewListenView Earnings Details
7/27/2016Q2 2016$0.55$0.70$8.3481 billion$9.2150 billionViewN/AView Earnings Details
4/27/2016Q1 2016$0.60$0.57$8.5866 billion$8.9235 billionViewN/AView Earnings Details
2/3/2016Q4 2015$0.52$0.55$9.3563 billion$9.6170 billionViewN/AView Earnings Details
10/28/2015Q3$0.60$0.71$6.0708 billion$6.1270 billionViewN/AView Earnings Details
7/29/2015Q215$0.4970$0.53$9.1446 billion$9.0198 billionViewN/AView Earnings Details
5/6/2015Q115$0.55$0.48$8.5525 billion$8.5123 billionViewN/AView Earnings Details
2/4/2015Q414$0.86$0.82$6.1427 billion$6.1860 billionViewN/AView Earnings Details
10/22/2014Q314$0.79$0.90$9.7556 billion$9.1195 billionViewListenView Earnings Details
7/23/2014Q114$0.71$0.65$10.1307 billion$9.4721 billionViewN/AView Earnings Details
4/30/2014Q413$0.72$0.70$10.3571 billion$9.4402 billionViewN/AView Earnings Details
2/5/2014Q4$0.30$0.30$6.8377 billion$6.9060 billionViewN/AView Earnings Details
10/23/2013Q313$0.31$10.31 billion$10.09 billionViewN/AView Earnings Details
7/24/2013$0.26$0.26$6.6180 billionViewN/AView Earnings Details
4/25/2013Q1 2013$0.77$0.82$10.1273 billion$9.8746 billionViewN/AView Earnings Details
2/6/2013Q4 2012$0.96$1.04ViewN/AView Earnings Details
10/31/2012Q3 2012$0.89$0.85ViewN/AView Earnings Details
7/25/2012Q2 2012$0.84$0.82ViewN/AView Earnings Details
4/25/2012$0.29$0.2730ViewN/AView Earnings Details
2/7/2012$0.30$0.2840ViewN/AView Earnings Details
10/26/2011Q3 2011$0.90$0.89ViewN/AView Earnings Details
7/26/2011Q2 2011$0.77$0.81ViewN/AView Earnings Details
4/27/2011Q1 2011$1.00$1.02ViewN/AView Earnings Details
2/3/2011Q4 2010$0.88$0.91ViewN/AView Earnings Details
7/21/2010Q2 2010$0.88$0.10ViewN/AView Earnings Details
4/28/2010Q1 2010$0.86$0.93ViewN/AView Earnings Details
2/7/2010Q4 2009$1.12$1.14ViewN/AView Earnings Details
11/2/2009Q3 2009$0.96$0.93ViewN/AView Earnings Details
7/22/2009Q2 2009$0.86$1.02ViewN/AView Earnings Details
2/5/2009Q4 2008$0.80$0.81ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

GlaxoSmithKline (NYSE:GSK) Dividend Information

GlaxoSmithKline pays an annual dividend of $2.10 per share, with a dividend yield of 5.27%. GSK's next quarterly dividend payment will be made on Thursday, July 12. GlaxoSmithKline pays out 72.92% of its earnings out as a dividend.
Next Dividend:7/12/2018
Annual Dividend:$2.10
Dividend Yield:5.27%
Dividend Growth:-8.90% (3 Year Average)
Payout Ratio(s):72.92% (Trailing 12 Months of Earnings)
72.66% (Based on This Year's Estimates)
69.08% (Based on Next Year's Estimates)
54.70% (Based on Cash Flow)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/26/2018quarterly$0.52985.27%5/10/20185/11/20187/12/2018
2/7/2018Quarterly$0.63306.48%2/22/20182/23/20184/12/2018
10/26/2017quarterly$0.50375.51%11/9/201711/10/20171/11/2018
7/26/2017Quarterly$0.49104.88%8/9/20178/11/201710/12/2017
4/26/2017quarterly$0.48304.79%5/10/20175/12/20177/13/2017
2/8/2017quarterly$0.57105.76%2/22/20172/24/20174/13/2017
10/26/2016$0.459011/2/201611/4/20161/12/2017
7/27/2016$0.49408/10/20168/12/201610/13/2016
4/28/2016$0.54905/11/20165/13/20167/14/2016
10/28/2015$0.577011/10/201511/13/20151/14/2016
5/7/2015quarterly$0.57695.22%5/13/20155/15/20157/9/2015
2/5/2015quarterly$0.69526.05%2/18/20152/20/20154/9/2015
10/23/2014quarterly$0.61305.41%11/5/201411/7/20141/8/2015
7/24/2014quarterly$0.64825.18%8/6/20148/8/201410/2/2014
5/1/2014quarterly$0.644.62%5/14/20145/16/20147/10/2014
2/5/2014$0.752/19/20142/21/20144/10/2014
2/6/2014quarterly$0.74965.73%2/19/20142/21/20144/10/2014
10/24/2013quarterly$0.61614.76%11/13/201311/15/20131/9/2014
7/25/2013quarterly$0.55324.27%8/7/20138/9/201310/3/2013
4/25/2013quarterly$0.55024.25%5/8/20135/10/20137/11/2013
2/7/2013quarterly$0.06900.61%2/20/20132/22/20134/11/2013
(Data available from 1/1/2013 forward)

Insider Trades

GlaxoSmithKline (NYSE GSK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 11.10%
Insider Trading History for GlaxoSmithKline (NYSE:GSK)
Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE GSK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/6/2017Plc GlaxosmithklineMajor ShareholderBuy428,571$14.00$5,999,994.00View SEC Filing  
10/24/2016Plc GlaxosmithklineMajor ShareholderBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

GlaxoSmithKline (NYSE GSK) News Headlines

Source:
DateHeadline
Venture Capitalists Put $260 Million Into New Chinese BiotechVenture Capitalists Put $260 Million Into New Chinese Biotech
finance.yahoo.com - May 24 at 8:59 AM
GlaxoSmithKline (GSK) Indian Consumer Unit Receives Frenzy of Interest - Economic TimesGlaxoSmithKline (GSK) Indian Consumer Unit Receives Frenzy of Interest - Economic Times
www.streetinsider.com - May 23 at 4:58 PM
$0.78 EPS Expected for GlaxoSmithKline (GSK) This Quarter$0.78 EPS Expected for GlaxoSmithKline (GSK) This Quarter
www.americanbankingnews.com - May 22 at 11:10 PM
BofA/Merrill Lynch Remains Neutral on GlaxoSmithKline (GSK) as FDA and EMA Announce InvestigationsBofA/Merrill Lynch Remains Neutral on GlaxoSmithKline (GSK) as FDA and EMA Announce Investigations
www.streetinsider.com - May 21 at 5:01 PM
BRIEF-GlaxoSmithKline Receives US Approval Of Arnuity Ellipta For Use In Children From 5 Years Old Who Suffer ...BRIEF-GlaxoSmithKline Receives US Approval Of Arnuity Ellipta For Use In Children From 5 Years Old Who Suffer ...
www.reuters.com - May 21 at 5:01 PM
Regulators flag possible birth defect link to GSKs HIV drugRegulators flag possible birth defect link to GSK's HIV drug
finance.yahoo.com - May 18 at 4:58 PM
Analysts’ Recommendations for AstraZeneca as of May 15Analysts’ Recommendations for AstraZeneca as of May 15
finance.yahoo.com - May 16 at 5:14 PM
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual MeetingMyxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 16 at 5:14 PM
AstraZeneca’s 1Q18 Estimates: CVMD ProductsAstraZeneca’s 1Q18 Estimates: CVMD Products
finance.yahoo.com - May 16 at 9:30 AM
Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) Drug Overview 2018: A Fixed-Dose Combination of an ...Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) Drug Overview 2018: A Fixed-Dose Combination of an ...
www.businesswire.com - May 14 at 4:58 PM
AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD StudyAstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study
finance.yahoo.com - May 14 at 10:06 AM
Another tenant inks deal for former GSK campus in RTPAnother tenant inks deal for former GSK campus in RTP
www.bizjournals.com - May 12 at 4:59 PM
Nucala (mepolizumab; GlaxoSmithKline) Drug Overview 2018 - ResearchAndMarkets.comNucala (mepolizumab; GlaxoSmithKline) Drug Overview 2018 - ResearchAndMarkets.com
www.businesswire.com - May 11 at 5:22 PM
What’s behind Teva’s $706 Million Impairment Charges in 1Q18?What’s behind Teva’s $706 Million Impairment Charges in 1Q18?
finance.yahoo.com - May 11 at 5:22 PM
Form FWP GLAXOSMITHKLINE PLC Filed by: GLAXOSMITHKLINE CAPITAL INCForm FWP GLAXOSMITHKLINE PLC Filed by: GLAXOSMITHKLINE CAPITAL INC
www.streetinsider.com - May 11 at 9:49 AM
Form FWP GLAXOSMITHKLINE PLC Filed by: GLAXOSMITHKLINE CAPITAL PLCForm FWP GLAXOSMITHKLINE PLC Filed by: GLAXOSMITHKLINE CAPITAL PLC
www.streetinsider.com - May 11 at 9:49 AM
GlaxoSmithKline Target of Unusually Large Options Trading (GSK)GlaxoSmithKline Target of Unusually Large Options Trading (GSK)
www.americanbankingnews.com - May 11 at 6:58 AM
GlaxoSmithKline (GSK) Given Consensus Recommendation of "Hold" by AnalystsGlaxoSmithKline (GSK) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 10 at 5:45 PM
June 29th Options Now Available For GlaxoSmithKline (GSK)June 29th Options Now Available For GlaxoSmithKline (GSK)
www.nasdaq.com - May 10 at 4:59 PM
Merck Focuses on Vaccines and Hospital Specialty Businesses in 2018Merck Focuses on Vaccines and Hospital Specialty Businesses in 2018
finance.yahoo.com - May 10 at 4:59 PM
Ex-Dividend Reminder: Glaxosmithkline, JM Smucker and DanaEx-Dividend Reminder: Glaxosmithkline, JM Smucker and Dana
www.nasdaq.com - May 8 at 5:05 PM
Follow These Dividend Leaders For 5% To 12% Yields Plus UpsideFollow These Dividend Leaders For 5% To 12% Yields Plus Upside
finance.yahoo.com - May 6 at 5:25 PM
GlaxoSmithKline (GSK) Stock Rating Lowered by ValuEngineGlaxoSmithKline (GSK) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 5 at 2:27 PM
Zacks: Analysts Expect GlaxoSmithKline (GSK) to Post $0.78 Earnings Per ShareZacks: Analysts Expect GlaxoSmithKline (GSK) to Post $0.78 Earnings Per Share
www.americanbankingnews.com - May 5 at 1:24 PM
Emergent (EBS) Misses on Q1 Earnings, Retains 2018 ViewEmergent (EBS) Misses on Q1 Earnings, Retains 2018 View
finance.yahoo.com - May 4 at 5:11 PM
Form 6-K GLAXOSMITHKLINE PLC For: May 03Form 6-K GLAXOSMITHKLINE PLC For: May 03
www.streetinsider.com - May 3 at 4:59 PM
These Pharma Stocks Offer the Most Upside PotentialThese Pharma Stocks Offer the Most Upside Potential
finance.yahoo.com - May 2 at 4:59 PM
Comparing Analysts’ Views on Sanofi and GlaxoSmithKlineComparing Analysts’ Views on Sanofi and GlaxoSmithKline
finance.yahoo.com - May 2 at 4:59 PM
GlaxoSmithKline’s Vaccine Business in 1Q18GlaxoSmithKline’s Vaccine Business in 1Q18
finance.yahoo.com - April 30 at 9:57 AM
GlaxoSmithKline Announces Quarterly Dividend of $0.53 (GSK)GlaxoSmithKline Announces Quarterly Dividend of $0.53 (GSK)
www.americanbankingnews.com - April 26 at 6:36 PM
Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales SolidGlaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid
finance.yahoo.com - April 26 at 4:56 PM
GSK Tries to Fix Pharma on a BudgetGSK Tries to Fix Pharma on a Budget
www.bloomberg.com - April 26 at 8:50 AM
Currency and pricing squeeze GlaxoSmithKline as new shingles vaccine shinesCurrency and pricing squeeze GlaxoSmithKline as new shingles vaccine shines
www.cnbc.com - April 25 at 4:58 PM
Glaxo's Shingles Vaccine 'Encouraging' But Shares Dip On Quarterly LagGlaxo's Shingles Vaccine 'Encouraging' But Shares Dip On Quarterly Lag
finance.yahoo.com - April 25 at 4:58 PM
Analysts’ Views on Sanofi, Pre-1Q18 Earnings ReleaseAnalysts’ Views on Sanofi, Pre-1Q18 Earnings Release
finance.yahoo.com - April 25 at 4:58 PM
Stronger pound weighs on revenues at drugmaker GSKStronger pound weighs on revenues at drugmaker GSK
finance.yahoo.com - April 25 at 4:58 PM
GlaxoSmithKline (GSK) Releases  Earnings Results, Misses Estimates By $0.01 EPSGlaxoSmithKline (GSK) Releases Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - April 25 at 2:54 PM
GlaxoSmithKline plc Shares Sink on Q1 Earnings MissGlaxoSmithKline plc Shares Sink on Q1 Earnings Miss
investorplace.com - April 25 at 12:33 PM
Stronger pound hinders GlaxoSmithKlineStronger pound hinders GlaxoSmithKline
www.ft.com - April 25 at 9:11 AM
Currency and pricing squeeze GSK as new shingles vaccine shinesCurrency and pricing squeeze GSK as new shingles vaccine shines
finance.yahoo.com - April 25 at 9:11 AM
BRIEF-Glaxosmithkline Says FDA Approves Expanded Indication For Trelegy Ellipta In The USBRIEF-Glaxosmithkline Says FDA Approves Expanded Indication For Trelegy Ellipta In The US
www.reuters.com - April 24 at 4:55 PM
Form 6-K GLAXOSMITHKLINE PLC For: Apr 24Form 6-K GLAXOSMITHKLINE PLC For: Apr 24
www.streetinsider.com - April 24 at 4:55 PM
Ozempic Could Be Potential Driver for Novo Nordisk in 2018Ozempic Could Be Potential Driver for Novo Nordisk in 2018
finance.yahoo.com - April 24 at 4:55 PM
Form 6-K GLAXOSMITHKLINE PLC For: Apr 20Form 6-K GLAXOSMITHKLINE PLC For: Apr 20
www.streetinsider.com - April 20 at 5:02 PM
What's in the Cards for Glaxo (GSK) This Earnings Season?What's in the Cards for Glaxo (GSK) This Earnings Season?
finance.yahoo.com - April 20 at 5:02 PM
Sanofi to Divest European Generic Unit, Streamline BusinessSanofi to Divest European Generic Unit, Streamline Business
finance.yahoo.com - April 19 at 5:22 PM
GlaxoSmithKline (GSK) Downgraded to "Hold" at Zacks Investment ResearchGlaxoSmithKline (GSK) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 19 at 12:49 PM
GlaxoSmithKline (GSK) Scheduled to Post Quarterly Earnings on WednesdayGlaxoSmithKline (GSK) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 19 at 8:47 AM
GSK grabs Roche cancer expert to lead pharma pipeline dealsGSK grabs Roche cancer expert to lead pharma pipeline deals
finance.yahoo.com - April 18 at 4:58 PM
Novartis’s 1Q18 Estimates: Expectations for AlconNovartis’s 1Q18 Estimates: Expectations for Alcon
finance.yahoo.com - April 18 at 4:58 PM

SEC Filings

GlaxoSmithKline (NYSE:GSK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GlaxoSmithKline (NYSE:GSK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GlaxoSmithKline (NYSE GSK) Stock Chart for Monday, May, 28, 2018

Loading chart…

This page was last updated on 5/28/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.